Ze Tian

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft‐Versus‐Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real‐World, Retrospective Multicenter Study (VAST Study)

Leqing Cao, Yi Xia, Song Xue, Jianping Zhang et autres

Steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation. Vedolizumab could be used as the second- or third-line treatment of GI-aGVHD. Our real-world, retrospective multicenter study, in which 100 SR-GI-aGVHD …

cn (code pays fourni par la source)

Vedolizumab for steroid-refractory gastrointestinal acute graft-versus-host disease: A real-world VAST study

Leqing Cao, Yi Xia, Song Xue, Na Xu et autres

Abstract Background: Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly for those with gastrointestinal (GI) involvement. Vedolizumab which can disrupt the homing of T cells to gut lymphoid tissue …

cn (code pays fourni par la source)

Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report

Jun Kong, Ze Tian, Dao-Xing Deng, Xiao‐Dong Mo

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). With mortality rates up to 90% without timely treatment, effective management remains a challenge. Complement dysregulation plays a central role in TA-TMA pathogenesis. We reported two TA-TMA cases …

cn (code pays fourni par la source)

T cell receptor mimic CAR T cells targeting cathepsin G signal peptide

Jun Yan, Chunhua Shi, Guojun Yang, Ze Tian et autres

us (code pays fourni par la source)

Immunotherapy targeting a leader sequence cathepsin G-derived peptide

Chunhua Shi, Ze Tian, Jun Yan, Mao Zhang et autres

Myeloid azurophil granules provide a rich source of intracellular leukemia antigens. Cathepsin G (CG) is a serine protease that has higher expression in acute myeloid leukemia (AML) blasts in comparison to normal myeloid progenitors. Based on the unique biology of HLA-A*0201 (HLA-A2), …

us (code pays fourni par la source)

Immunotherapy Targeting a Leader Sequence Cathepsin G-Derived Peptide

Gheath Alatrash, Chunhua Shi, Ze Tian, Jun Yan et autres

us (code pays fourni par la source)

Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Ze Tian, Chunhua Shi, Guojun Yang, Jason Allen et autres

Author notes These authors contributed equally: Chunhua Shi, Guojun Yang, Jason K. Allen, Qing Shi Authors and Affiliations ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Ze Tian, Chunhua Shi, Guojun Yang, Jason K. Allen, Qing Shi, …

us (code pays fourni par la source)

AML Immunotherapy Using a Novel Tcrm-Based Bispecific Antibody That Targets a Leader Sequence Peptide Derived from Cathepsin G

Chunhua Shi, Ze Tian, Jun Yan, Mao Zhang et autres

Introduction: Myeloid azurophil granules provide a rich source of intracellular leukemia antigens. Cathepsin G (CG) is a serine protease that has higher expression in AML blasts in comparison to normal myeloid progenitors. Based on the unique biology of HLA-A*0201 (HLA-A2), in which …

us (code pays fourni par la source)

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

Ze Tian, Chunhua Shi, Guojun Yang, Jason Allen et autres

Patients harboring CRLF2-rearranged B-lineage acute lymphocytic leukemia (B-ALL) face a 5-year survival rate as low as 20%. While significant gains have been made to position targeted therapies for B-ALL treatment, continued efforts are needed to develop therapeutic options with improved duration of …

us (code pays fourni par la source)

Abstract 2995: Cross-presented serine proteases as immunotherapy targets for lung cancer and osteosarcoma

Amber Gibson, Pariya Sukhumalchandra, Céline Kerros, Na Qiao et autres

Abstract Background: Immunotherapy is the standard of care for many solid tumor malignancies. However, due to a paucity of known tumor antigens in non-small cell lung cancer (NSCLC) and osteosarcoma (OS), identification of novel immunogenic antigens is needed. Our group has experience …

us (code pays fourni par la source)

Abstract 5655: preclinical development of a novel anti-tslpr bispecific antibody 1b7/cd3 targeting crlf2-rearranged ph-like b-all

Ze Tian, Chunhua Shi, Amin AI-Shami, GuoJun Yong et autres

Abstract Acute lymphocytic leukemia (ALL) is the most common form of leukemia in childhood and adolescence. Outcomes of relapsed/refractory adult B-ALL remain dismal with long-term survival of less than 10%. Although targeted therapies such as blinatumomab, inotuzumab ozogamicin, and CD19 CAR T …

us (code pays fourni par la source)

Development of Fully Human, Bispecific Antibodies that Effectively Block Omicron Variant Pseudovirus Infections

Jason Allen, Michelle A. González, Jasbir Kaur, Melinda Smith et autres

Abstract The emergence of highly immune invasive and transmissible variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has decreased the effectiveness of existing vaccines. It is, therefore, critical to develop effective and safe therapeutics for SARS-CoV-2 infections, especially for the most …

us (code pays fourni par la source)